According to a study led by researchers at UCLA, the Alzheimer’s drug Leqembi would raise future costs for Medicare by $2 billion to $5 billion a year. Leqembi, sold for …
Study finds Alzheimer’s drug Leqembi would cost Medicare up to $5 billion a year Read More »
By Jeffrey Gelblum, MD As a practicing neurologist with over 25 years of experience treating Alzheimer’s disease, I strongly oppose the proposed intention of Centers for Medicare & Medicaid Services …
Medicare to Restrict Coverage of Anti-Amyloid Antibody Therapy for Alzheimer’s Patients Read More »
Biogen is providing its new Alzheimer’s drug Aduhelm free to some patients because of slow reviews by Medicare. There is a division among doctors about whether Aduhelm, also known as …
Biogen Offering Free Alzheimer’s Drug Aduhelm to Patients Read More »
Dr. Jeff Gelblum, a board-certified Neurologist with First Choice Neurology, makes great use of the cognitive assessment in his daily practice. Gelblum states, “this activity enables me to determine the …
By Dr. Antonio Mesa Selecting the right health insurance plan is a very important decision that can have a major impact on a person’s health and quality of life. The …
